“…Regarding the care of AMI, the rate of use of glycoprotein IIb/IIIa inhibitors remained stable and low (6.4 % to 7.5 %) during the study period, which has been a trend in literature since the advent of clopidogrel, new antiaggregants, and the use of thrombus aspiration catheters 12 The more frequent use of aspiration catheters in the second period group coincides with the publication, in 2008, of the TAPAS trial results, which showed the superiority of thrombus aspiration technique to treat AMI with ST-segment elevation, reducing cardiac mortality combined with non fatal reinfarction within one year. 15,16 The continuous improvement of the material used in the PCI, such as balloons and stents of better navigability and smaller calibre, guide wires with different characteristics of flexibility and stiffness, and drug-eluting stents, for instance, has increased the possibilities of using of the percutaneous technique in patients with greater angiographic complexity. This was also observed in the present study, with patients from P2 showing more severe coronary disease, such as multivessel involvement, thrombotic lesions, and diffuse (> 20 mm) and bifurcation lesions, requiring the use of longer and pharmacological stents.…”